[
  {
    "ts": null,
    "headline": "Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination",
    "summary": "Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human Services. Including Moderna Inc (NASDAQ:MRNA), several stocks witnessed a decline as Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Goldman Sachs hosted an investor lunch with Moderna CEO Stéphane Bancel, President Stephen Hoge,",
    "url": "https://finnhub.io/api/news?id=3115191d1307192edc0f06de31ae8cd898df73d9301976e1e5262596a91425e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731954279,
      "headline": "Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination",
      "id": 131460096,
      "image": "https://media.zenfs.com/en/Benzinga/dc3efb4f2891f834b8f5ef3bb7da5c96",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human Services. Including Moderna Inc (NASDAQ:MRNA), several stocks witnessed a decline as Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Goldman Sachs hosted an investor lunch with Moderna CEO Stéphane Bancel, President Stephen Hoge,",
      "url": "https://finnhub.io/api/news?id=3115191d1307192edc0f06de31ae8cd898df73d9301976e1e5262596a91425e3"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Flat After Last Week's Selloff - Health Care Roundup",
    "summary": "Health-care companies were more or less flat as traders rotated back into a sector that took the brunt of last week's selloff. Shares of vaccine makers such as Moderna and Novavax rose, following...",
    "url": "https://finnhub.io/api/news?id=2f5fa8b02a32ba0f4d34c6f4af3463463c1b3f294cd5a8f61c4e752884214f11",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731950052,
      "headline": "Health Care Flat After Last Week's Selloff - Health Care Roundup",
      "id": 131460626,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "Health-care companies were more or less flat as traders rotated back into a sector that took the brunt of last week's selloff. Shares of vaccine makers such as Moderna and Novavax rose, following...",
      "url": "https://finnhub.io/api/news?id=2f5fa8b02a32ba0f4d34c6f4af3463463c1b3f294cd5a8f61c4e752884214f11"
    }
  },
  {
    "ts": null,
    "headline": "Moderna stock climbs as HSBC upgrades to Buy on underestimated pipeline potential",
    "summary": "Investing.com -- Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.",
    "url": "https://finnhub.io/api/news?id=547760d9d141dc9e633fdb1fa96c55e7206648b7d817eecc01a04e9aa262188f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731945452,
      "headline": "Moderna stock climbs as HSBC upgrades to Buy on underestimated pipeline potential",
      "id": 131447286,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Investing.com -- Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.",
      "url": "https://finnhub.io/api/news?id=547760d9d141dc9e633fdb1fa96c55e7206648b7d817eecc01a04e9aa262188f"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy",
    "summary": "Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.",
    "url": "https://finnhub.io/api/news?id=b02e8a4d54768a2158d8e4696333123f7e491d50d8bf941ea6c0fab1b2b86d91",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731903372,
      "headline": "Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy",
      "id": 131438224,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/601800909/image_601800909.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.",
      "url": "https://finnhub.io/api/news?id=b02e8a4d54768a2158d8e4696333123f7e491d50d8bf941ea6c0fab1b2b86d91"
    }
  }
]